Description

Cell line development is a major step for examining the efficiency of drug discovery, toxicity and in vitro testing. It reduces time, effort and cost, which minimises the chance of research drugs failing at the clinical trial stage. The global cell line development market is poised to grow by US$ 4.5 billion during 2022-2028, progressing at a CAGR of 11.7% during the forecast period, according to data and analytics company StrategyHelix.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for cell line development. The global cell line development market is segmented on the basis of product, source, type, application, and region. By product, the global cell line development market has been segmented into equipment, media and reagents. In 2021, the media and reagents segment made up the largest share of revenue generated by the cell line development market. Based upon source, the global cell line development market is categorized into mammalian, non-mammalian. The mammalian segment was the largest contributor to the global cell line development market in 2021. On the basis of type, the global cell line development market has been segmented into continuous cell lines, hybridomas, primary cell lines, recombinant cell lines. By application, the global cell line development market has been segmented into bioproduction, drug discovery, tissue engineering, others. Geographically, the global cell line development market is segmented into Asia Pacific, Europe, North America, Rest of the World (RoW).

The global cell line development market is highly competitive. The report also includes the profiles of leading companies such as BioFactura Inc., Corning Incorporated, Fujifilm Diosynth Biotechnologies, GE Healthcare, Horizon Discovery Group plc, LakePharma Inc. (Curia Global Inc.), Lonza Group AG, Merck KGaA, Rentschler Biopharma SE, Sartorius AG, Selexis SA (JSR Corporation), Thermo Fisher Scientific Inc., WuXi AppTec Co. Ltd.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the cell line development market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Product: equipment, media and reagents
Source: mammalian, non-mammalian
Type: continuous cell lines, hybridomas, primary cell lines, recombinant cell lines
Application: bioproduction, drug discovery, tissue engineering, others
Region: Asia Pacific, Europe, North America, Rest of the World (RoW)
Years considered: this report covers the period 2018 to 2028

Key Benefits for Stakeholders

– Get a comprehensive picture of the global cell line development market
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Cell line development market overview
Part 3. Market breakdown by product
– Equipment
– Media and reagents
Part 4. Market breakdown by source
– Mammalian
– Non-mammalian
Part 5. Market breakdown by type
– Continuous cell lines
– Hybridomas
– Primary cell lines
– Recombinant cell lines
Part 6. Market breakdown by application
– Bioproduction
– Drug discovery
– Tissue engineering
– Others
Part 7. Market breakdown by region
– Asia Pacific
– Europe
– North America
– Rest of the World (RoW)
Part 8. Key companies
– BioFactura, Inc.
– Corning Incorporated
– Fujifilm Diosynth Biotechnologies
– GE Healthcare
– Horizon Discovery Group plc
– LakePharma, Inc. (Curia Global, Inc.)
– Lonza Group AG
– Merck KGaA
– Rentschler Biopharma SE
– Sartorius AG
– Selexis SA (JSR Corporation)
– Thermo Fisher Scientific Inc.
– WuXi AppTec Co., Ltd.
About StrategyHelix
Disclaimer